Premium
Antiparkinsonian agents and long‐term neuroleptic treatment
Author(s) -
Gerlach J.,
Rasmussen P. T.,
Hansen L.,
Kristjansen P.
Publication year - 1977
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1977.tb00170.x
Subject(s) - thioridazine , anticholinergic , parkinsonism , haloperidol , placebo , clozapine , medicine , chlorpromazine , perphenazine , fluphenazine , anticholinergic agents , anesthesia , schizophrenia (object oriented programming) , trihexyphenidyl , psychology , psychiatry , disease , alternative medicine , pathology , dopamine
The need for medication with anticholinergic antiparkinsonian drugs was examined in 118 schizophrenic patients under long‐term neuroleptic treatment. It was found that 1) none of 18 patients under treatment with low mg potency neuroleptics (chlorprothixene, clozapine, and thioridazine) had any need for anticholinergics; 2) of 60 patients under treatment with short‐acting high mg potency neuroleptics (perphenazine ≥ 16 mg daily and haloperidol ≥ 2 mg daily) nine patients (15 %) required medication with anticholinergics, whereas 3) of 40 patients under treatment with long‐acting (depot) neuroleptics, 17 (43 %) had a need for anticholinergic medication; and 4) no patient factors predisposing to the need for continued antiparkinsonian treatment could be identified. In an additional double‐blind cross‐over study of 12 patients presenting persisting neuroleptic‐induced parkinsonism, it was found that G 31.406 (a new potentially antiparkinsonian drug), compared with placebo, had an antiparkinsonian effect (P ≥ 0.01) as well as an antidepressant effect (P < O.O5). G 31.406 resulted in an improvement in anxiety and schizophrenia‐score in some patients. Compared with placebo, orphenadrine had a more questionable effect on parkinsonism (0.05 < P < 0.01) and no significant effect on mental symptoms. There were no significant differences between the effects of G 31.406 and orphenadrine.